1e
19
1
49
2
2
18
1b
1d
18
42
3d
1d
2 29
1d
25
David C. Metz, MBBCh (MD equivalent)
78
3d
Professor CE of Medicine
28
b0
3
5f
Director, Acid Peptic Disorders Specialty Program, Digestive and Liver Center, Hospital of the University of Pennsylvania
97
Co-Director, Neuroendocrine Tumor Center, University of Pennsylvania Perelman School of Medicine
80
Full Clinical Member, Abramson Cancer Center, Cancer Therapeutics Program
11
Department: Medicine
4
1
b
1d
46
Contact information
49
4
3
3
1d
49
3400 Civic Center Boulevard
31 709 Perelman Center for Advanced Medicine
31 South Pavilion
Philadelphia, PA 19104
26
31 709 Perelman Center for Advanced Medicine
31 South Pavilion
Philadelphia, PA 19104
2e
Office: 215-662-3541
32 Fax: 215-349-5915
24
93
32 Fax: 215-349-5915
24
Email:
david.metz@uphs.upenn.edu
12
david.metz@uphs.upenn.edu
18
Publications
23 a
3
2
29
23 a
Links
ca Search PubMed for articles
97 Penn Medicine Abramson Cancer Center
f9 Penn Medicine Esophageal and Swallowing Disorders Program
a3 University of Pennsylvania Neuroendocrine Tumor Program
c
4
b
1f
ca Search PubMed for articles
97 Penn Medicine Abramson Cancer Center
f9 Penn Medicine Esophageal and Swallowing Disorders Program
a3 University of Pennsylvania Neuroendocrine Tumor Program
c
13
Education:
21 7 HS c
30 King David High School , 1975.
21 7 MD c
61 University of Witwatersrand Medical School, Johannesburg, South Africa. , 1982.
c
3
3
3
3
8a
Permanent link21 7 HS c
30 King David High School , 1975.
21 7 MD c
61 University of Witwatersrand Medical School, Johannesburg, South Africa. , 1982.
c
2 29
21
1e
1d
24
2b
29
27
23
ee Shih GL, Brensinger C, Katzka DA, Metz DC: Postprandial esophageal integrated acidity is a reliable predictor of GERD. Aliment Pharmacol Therap 21: 1475-1482, 2005.
143 Metz DC, Miner PB, Heuman DM, Chen Y, Sostek M: Comparison of the effects of intravenously and orally administered esomeprazole on acid output in patients with symptoms of gastro-esophageal reflux disease. Aliment Pharmacol Therap 22: 813-821, 2005.
146 Metz DC, Comer GM, Soffer E, Forsmark CE, Cryer B, Chey W, Pisegna JR: Three year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions. Aliment Pharmacol Therap 23: 437-444, 2006.
13c Pratha V, Hogan DL, Lynn RB, Field B, Metz DC: Intravenous Pantoprazole as Initial Treatment in Patients With Gastroesophageal Reflux Disease and a History of Erosive Esophagitis: A Randomized Clinical Trial. Dig Dis Sci 51: 1595-1601, 2006.
134 Blonski WC, Shih GL, Brensinger CM, Katzka DA, Metz DC: Analysis of the acidity index and integrated intragastric acidity in 645 patients presenting with gastroesophageal reflux disease symptoms. Sc J Gastroenterol 41: 382-389, 2006.
c7 Yang YX, Lewis JD, Epstein S, Metz DC: Chronic proton pump inhibitor therapy and hip fracture risk. JAMA 296: 1595-1601, 2006.
133 Lewis JD, Strom BL, Kimmel SE, Farrar J, Metz DC, Brensinger C, Nessel L, Localio AR: Predictors of recall of over-the-counter and prescription non-steroidal anti-inflammatory drug exposure. Pharmacoepidemiol Drug Saf 15: 39-45, 2006.
136 Howden C, Metz DC, Hunt B, Majid V, Kukulka M, Amer F, Samra N. : Dose-Response Evaluation of the Antisecretory Effect of Continuous Infusion Intravenous Lansoprazole Regimens over 48 Hours. Aliment Pharmacol Therap 23: 975-984, 2006.
124 Metz DC, Amer F, Hunt B, Majid V, Kukulka M. : Lansoprazole Regimens That Sustain Intragastric pH >6: An Evaluation of Intermittent Oral and Continuous IV Infusion Dosages. Aliment Pharmacol Therap 23: 985-995, 2006.
2c
7
1d
1f
Selected Publications
d1 Lau CT, Gefter WB, Metz DC: Radiographic appearance of a catheter-free wireless esophageal pH probe. Am J Roentgenol 184: S40-42, 2005.ee Shih GL, Brensinger C, Katzka DA, Metz DC: Postprandial esophageal integrated acidity is a reliable predictor of GERD. Aliment Pharmacol Therap 21: 1475-1482, 2005.
143 Metz DC, Miner PB, Heuman DM, Chen Y, Sostek M: Comparison of the effects of intravenously and orally administered esomeprazole on acid output in patients with symptoms of gastro-esophageal reflux disease. Aliment Pharmacol Therap 22: 813-821, 2005.
146 Metz DC, Comer GM, Soffer E, Forsmark CE, Cryer B, Chey W, Pisegna JR: Three year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions. Aliment Pharmacol Therap 23: 437-444, 2006.
13c Pratha V, Hogan DL, Lynn RB, Field B, Metz DC: Intravenous Pantoprazole as Initial Treatment in Patients With Gastroesophageal Reflux Disease and a History of Erosive Esophagitis: A Randomized Clinical Trial. Dig Dis Sci 51: 1595-1601, 2006.
134 Blonski WC, Shih GL, Brensinger CM, Katzka DA, Metz DC: Analysis of the acidity index and integrated intragastric acidity in 645 patients presenting with gastroesophageal reflux disease symptoms. Sc J Gastroenterol 41: 382-389, 2006.
c7 Yang YX, Lewis JD, Epstein S, Metz DC: Chronic proton pump inhibitor therapy and hip fracture risk. JAMA 296: 1595-1601, 2006.
133 Lewis JD, Strom BL, Kimmel SE, Farrar J, Metz DC, Brensinger C, Nessel L, Localio AR: Predictors of recall of over-the-counter and prescription non-steroidal anti-inflammatory drug exposure. Pharmacoepidemiol Drug Saf 15: 39-45, 2006.
136 Howden C, Metz DC, Hunt B, Majid V, Kukulka M, Amer F, Samra N. : Dose-Response Evaluation of the Antisecretory Effect of Continuous Infusion Intravenous Lansoprazole Regimens over 48 Hours. Aliment Pharmacol Therap 23: 975-984, 2006.
124 Metz DC, Amer F, Hunt B, Majid V, Kukulka M. : Lansoprazole Regimens That Sustain Intragastric pH >6: An Evaluation of Intermittent Oral and Continuous IV Infusion Dosages. Aliment Pharmacol Therap 23: 985-995, 2006.
2c